Press releases

Beactica appoints Magnus Björsne to its Board of Directors


Uppsala, Sweden, 18 November 2014

Beactica, the Swedish fragment-based drug discovery company, today announced the appointment of Dr Magnus Björsne to its Board of Directors. Dr Björsne, Executive Director at AstraZeneca BioVentureHub, brings more than 15 years of experience from the pharmaceutical industry to the Company.

"We are delighted to welcome Dr Björsne to the Board of Beactica. His extensive knowledge of drug discovery and business development will be of great value as Beactica continues to grow” said Dr Per Källblad, CEO of Beactica.

Dr Magnus Björsne is Executive Director at AstraZeneca BioVentureHub, an initiative to contribute to a more dynamic and competitive life science ecosystem in Scandinavia. He has worked at AstraZeneca in a number of senior roles, including Executive Director, Director and Associate Director in the areas of Busines Development and Lead Generation. He has been a member of AstraZeneca's global chemistry management team and responsible for lead generation chemistry globally within specific therapeutic areas. Magnus is a board member of SwedenBIO, the Swedish trade association for the life science sector. He has an executive MBA from Henley Management College and a Ph.D in organic chemistry from Stockholm University.

For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 560 880

About Beactica

Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes in oncology and CNS, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platform. Founded in 2006 based on research carried out at Uppsala University, Beactica has established a reputation as the leader in fragment-based drug discovery using SPR biosensor technology.